Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Document › Details

Cevec Pharmaceuticals GmbH. (9/19/14). "Press Release: Cevec Appoints New Management Team". Cologne.

Organisations Organisation Cevec Pharmaceuticals GmbH
  Group Cevec (Group)
  Organisation 2 Scil Proteins GmbH
  Today Navigo Proteins GmbH
  Group UV-Cap (Group)
Products Product CAP® technology (Cevec)
  Product 2 contract manufacturing (biologicals)
Persons Person Ubags, Frank (Cevec 201504– CEO before COO since 201409 before Coral BioNet + Scil Proteins + Kiadis + Rhein Biotech)
  Person 2 Tintrup, Hartmut (Cevec 201511– VP Business Developm Gene Therapy/Viruses before CBO joined 2010 before amaxa US)
     


CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology, today announced its new management team.

Wolfgang Kintzel remains Chief Executive Officer, Dr. Nicole Faust is appointed Chief Scientific Officer, Dr. Hartmut Tintrup is appointed Chief Business Officer and Frank Ubags joins as Chief Operating Officer.

"Our vision is to become the leading independent player for human cell line based clinical materials. This management team possesses all skills, competencies and experience to achieve this ambitious target."

"I am very pleased to welcome Frank Ubags to our team. Frank has an outstanding track record in the biopharmaceutical sector in establishing and implementing growth strategies. Together with him we have now accomplished a strong management team to lead CEVEC through its next stage of corporate growth" stated Wolfgang Kintzel, CEO at CEVEC.

Wolfgang Kintzel, Chief Executive Officer, biologist by training (MSc) joined Schering/Berlex gaining quickly more responsibility in various sales and marketing functions. With now more than 18 years of experience in different roles within the pharmaceutical, medical device and biotech industry in leading European and US based organizations he had full P&L responsibility up to 100 Mio €. Wolfgang managed organizations up to 170 employees. From 2000 - 2008 he built up amaxa AG as global VP Marketing & Sales from a true start-up situation to a fully integrated company complemented with an outstanding M&A experience in 2008 when the company was sold to Lonza Group Ltd., Switzerland. Wolfgang joined CEVEC in 2009 as Managing Director. Wolfgang holds several board assignments in European biotech companies

Frank Ubags, Chief Operating Officer, has more than 35 years of business experience in renowned companies. He joined the life science business in 1997 as CFO of Rhein Biotech. He led the IPO at the Neuer Markt in 1999 and initiated and executed the transformation of Rhein Biotech into a vaccines company through a major acquisition, 2 years later followed by a sale to Berna Biotech. Frank served from 2004 as CEO of the German Rhein Biotech operation and after its sale to Dynavax, he joined Kiadis Pharma in 2006 as CFO. In 2009 he joined Scil Proteins as CFO. After a successful financing round in 2011, he took over in 2012 the COO position for the Scil Proteins CMO operation where he led the company through a successful FDA inspection and he initiated the sale of Scil Proteins Production to Wacker Biotech. Frank holds several advisory positions in the field of protein production.

Dr. Nicole Faust, Chief Scientific Officer, holds a Ph.D. in Molecular and Cell Biology. After a post-doctoral period at the EMBL, Heidelberg, she joined Artemis-Pharmaceuticals GmbH, Cologne in 1999 where she took over responsibility for the Molecular Technology group as Associate Director R&D. In 2004 she started a position with amaxa GmbH, now Lonza Cologne GmbH. As Director R&D she was responsible for developing transfection technologies, for the cell-based assay program, and for establishing and running the cell line development services. She joined CEVEC in May 2011 as VP Development & Services and was appointed Chief Scientific Officer in 2014.

Dr. Hartmut Tintrup, Chief Business Officer, served previously as VP Business Development & Licensing at CEVEC and holds a Ph.D. in Neurochemistry from Frankfurt University, Germany. He spent 16 years in various positions of increasing responsibility at leading Biotech Companies in the US and Germany. Prior to joining CEVEC he held management positions at amaxa AG and Lonza in Industrial Sales and Tactical Marketing. Hartmut joined CEVEC in 2010 was appointed Chief Business Officer in 2014.


About CEVEC Pharmaceuticals GmbH - www.cevec.com

CEVEC offers the human amniocyte-based protein expression platform CAP for the transient and stable production of superior Biopharmaceuticals, CAP Cells are immortalized suspension cells for stable protein production developed by CEVEC. This non-tumor origin cell line exhibits high protein expression, has been adapted to serum-free suspension culture and shows post-translational modifications that are human-like, including authentic human glycosylation patterns. The technology allows for superior yields of complex (glyco-) proteins in a shorter time frame than traditional methods and has proven to be a versatile production platform for gene therapy vectors, viruses and vaccines.


Contact

Wolfgang Kintzel
CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Straße 62
D-51105 Germany
Fon +49 (0) 221 46020800
Fax +49 (0) 221 46020801
info@cevec.com

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for Cevec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px




» top